Agarwal's ASCO GU 2024 Must-Sees for Prostate Cancer

Neeraj Agarwal, MD, director of genitourinary oncology program and professor of medicine at the Huntsman Cancer Institute, University of Utah, highlights several exciting prostate cancer developments being presented at the upcoming 2024 Genitourinary Cancers Symposium.

Agarwal anticipates practice-changing data on sequencing AR pathway inhibitors [ARPI] and PARP inhibitors for metastatic castration-resistant prostate cancer (mCRPC), and unveils his own research on an effective tyrosine kinase inhibitor (TKI)/immunotherapy (IO) combination for progression after novel hormonal therapy.

Additionally, his colleague Umang Swami, MD, assistant professor in the division of oncology, Department of Internal Medicine at Huntsman Cancer Institute, University of Utah, will present new research on the genomic and immune landscape of metastatic prostate cancer by disease site. Agarwal concludes by emphasizing the value of this meeting and encourages viewers to participate in disseminating the new knowledge for global patient benefit.

Transcription:

0:09 | As usual, the ASCO GU meeting will continue to showcase the most recent advancements in the treatment for patients with prostate cancer. In fact the first presentation of the ASCO GU meeting will be on sequencing vs combination of ARPI plus PARP inhibitors in patients with newly diagnosed metastatic castration-resistant prostate cancer. I can assure [that] the data will be practice influencing. Another abstract I would like to highlight which I have the privilege of presenting is the combination of cabozantinib [Cometriq] plus atezolizumab [Tecentriq] as a first IO/TKI combination in the results of the CONTACT-02 to trial [NCT04446117]. For the first time, a TKI/IO combination has shown improved outcomes in patients with metastatic CRPC after disease progression on a novel hormonal therapy.

1:08 | We will also show the results of 1 of the many oral presentations by Umang Swami, MD, my colleague in Huntsman Cancer Institute, [who] will be presenting the data on the genomic transcriptomic and immune landscape of metastatic prostate cancer by disease sites. We will also see the results of many other trials which are going well, which we have been waiting for for the last many years. I think overall, the meeting is going to be very exciting and I encourage our listeners, our viewers, and my colleagues around the world to help us disseminate all that exciting data to our colleagues across the world to maximize the benefit to our patients across the planet.